BRPI0517999A - derivados de tetraidropirano como antidiabéticos - Google Patents

derivados de tetraidropirano como antidiabéticos

Info

Publication number
BRPI0517999A
BRPI0517999A BRPI0517999-8A BRPI0517999A BRPI0517999A BR PI0517999 A BRPI0517999 A BR PI0517999A BR PI0517999 A BRPI0517999 A BR PI0517999A BR PI0517999 A BRPI0517999 A BR PI0517999A
Authority
BR
Brazil
Prior art keywords
antidiabetics
tetrahydropyran derivatives
tetrahydropyran
derivatives
compounds
Prior art date
Application number
BRPI0517999-8A
Other languages
English (en)
Inventor
Werner Mederski
Amsterdam Christoph Van
Christa Burger
Hartmut Greiner
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0517999A publication Critical patent/BRPI0517999A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

DERIVADOS DE TETRAIDROPIRANO COMO ANTIDIABéTICOS. A invenção refere-se a compostos da fórmula (I), em que T, E, R, R', R", R˜, R� e R�' têm os significados indicados na reivindicação de patente 1, sendo adequados como antidiabéticos
BRPI0517999-8A 2004-12-03 2005-11-07 derivados de tetraidropirano como antidiabéticos BRPI0517999A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004058449A DE102004058449A1 (de) 2004-12-03 2004-12-03 Tetrahydropyranderivate
PCT/EP2005/011875 WO2006058597A1 (de) 2004-12-03 2005-11-07 Tetrahydropyranderivate als antidiabetika

Publications (1)

Publication Number Publication Date
BRPI0517999A true BRPI0517999A (pt) 2008-10-21

Family

ID=35735074

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517999-8A BRPI0517999A (pt) 2004-12-03 2005-11-07 derivados de tetraidropirano como antidiabéticos

Country Status (14)

Country Link
US (1) US20070299065A1 (pt)
EP (1) EP1817323A1 (pt)
JP (1) JP2008521842A (pt)
KR (1) KR20070085568A (pt)
CN (1) CN101068823A (pt)
AR (1) AR052256A1 (pt)
AU (1) AU2005312142A1 (pt)
BR (1) BRPI0517999A (pt)
CA (1) CA2589105A1 (pt)
DE (1) DE102004058449A1 (pt)
MX (1) MX2007006397A (pt)
RU (1) RU2007124681A (pt)
WO (1) WO2006058597A1 (pt)
ZA (1) ZA200705258B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
AR065034A1 (es) * 2007-01-26 2009-05-13 Boehringer Ingelheim Int Metodos para prevenir y tratar trastornos neurodegenerativos
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
MX2010012656A (es) 2008-05-22 2010-12-20 Squibb Bristol Myers Co Metodo para tratar la hiperuricemia empleando un inhibidor de sglt2 y composicion que contiene el mismo.
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
MX2013013734A (es) * 2011-05-26 2014-02-27 Tfchem Familia de carba-azucares de arilo, heteroarilo, o-arilo y o-heteroarilo.
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103721261B (zh) * 2014-01-07 2016-01-20 深圳奥萨医药有限公司 含有sglt2抑制剂和b族维生素的药物组合物及其用途
MX2021000601A (es) 2018-07-19 2021-04-13 Astrazeneca Ab Metodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma.
US20220023252A1 (en) 2020-07-27 2022-01-27 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
WO2022208172A1 (en) 2021-04-01 2022-10-06 Astrazeneca Uk Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
WO2023144722A1 (en) 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
DE10258007B4 (de) * 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel

Also Published As

Publication number Publication date
CA2589105A1 (en) 2006-06-08
ZA200705258B (en) 2008-06-25
DE102004058449A1 (de) 2006-06-14
KR20070085568A (ko) 2007-08-27
AU2005312142A1 (en) 2006-06-08
AR052256A1 (es) 2007-03-07
CN101068823A (zh) 2007-11-07
MX2007006397A (es) 2007-06-22
JP2008521842A (ja) 2008-06-26
US20070299065A1 (en) 2007-12-27
EP1817323A1 (de) 2007-08-15
WO2006058597A1 (de) 2006-06-08
RU2007124681A (ru) 2009-01-10

Similar Documents

Publication Publication Date Title
BRPI0517999A (pt) derivados de tetraidropirano como antidiabéticos
BRPI0518758A2 (pt) compostos de acetamida como fungicidas
BRPI0412851A (pt) benzamidazóis de n-metila-substituìdos
BRPI0617167B8 (pt) sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação
BR0307960A (pt) N-aminoacetil-pirrolidina-2-carbonitrilas e seu uso como inibidores de ddp-iv
BRPI0513184A (pt) derivados de 2-carbamida-4-feniltiazol, preparação dos mesmos e aplicação dos mesmos em terapia
BRPI0510273A (pt) derivados de tetraazabenzo[e]azuleno e análogos destes
BRPI0415773A (pt) derivados de indolinona e sua aplicação no tratamento de estados de doença tais como cáncer
BR0111981A (pt) herbicidas de piridina substituìda
BR0309556A (pt) Inibidores de metaloproteinase pirimidina-2,4,6-triona
BRPI0518301A2 (pt) inseticidas
BRPI0513379A (pt) derivados de sulfonamida
BRPI0513085A (pt) 8-pirrolidinoxantinas bicìclicas substituìdas, e uso das mesmas como inibidoras de dipeptidil peptidase
NO20070089L (no) DPP-IV inhibitorer
BR0308211A (pt) Cumarinas úteis como biomarcadores
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5
BR0316609A (pt) Sinomenina e compostos de sinomenina, sìntese e uso
BR0306922A (pt) N-pirazinil-fenilsulfonamidas e seu uso no tratamento de doenças mediadas por quimocina
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.
UY28917A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas composiciones farmaceuticas y su uso terapeutico
BRPI0415203A (pt) pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios
UY29859A1 (es) Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica
BRPI0512580A (pt) derivados de n-fenilpirazol como pesticidas
BR0307461A (pt) Derivados de quinazolinona e seu uso como agonistas de cb
SE0401969D0 (sv) Piperidine derivatives

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired